Coupang shares fall 3% as revenue misses expectations

Featured in:
abcd

SEATTLE – Coupang, Inc. (NYSE:CPNG) reported second-quarter results that beat analyst estimates, but revenue fell low of expectations, sending the stock down 3% in after-market trading.

The South Korean e-commerce giant reported adjusted earnings per share of $0.07, beating analysts’ consensus of -$0.01. However, revenue for the quarter came in at $7.32 billion, missing estimates of $7.4 billion. Despite the lack of revenue, Coupang’s top line rose 25% YoY on a reported basis and 30% YoY on a currency-neutral basis.

Coupang’s gross profit rose 41% year-over-year to $2.1 billion, with gross profit margin improving 310 basis points to 29.3%. The company’s Product Commerce segment, which includes its core e-commerce business, saw net revenue grow 13% year-over-year to $6.4 billion. Active customers in the segment grew 12% year-over-year to 21.7 million.

sadasda

“We continued to see higher levels of engagement from our customers this quarter as we continue to focus on delivering greater choice, service and savings to our customers,” said Gaurav Anand, CFO of Coupang.

The company’s Developing Offerings segment, which includes international operations, Coupang Eats, Play, Fintech and Farfetch (OTC:), saw significant growth, with net revenue increasing 472% year over year to $892 million. However, the segment posted an adjusted EBITDA loss of $200 million.

Coupang’s total adjusted EBITDA for the quarter was $330 million, with a margin of 4.5%, down 60 basis points from the prior year. The company’s cash flow from operating activities for the last twelve months increased $250 million year-over-year to $2.2 billion.

This article was generated with the assist of AI and reviewed by an editor. For more information, see our T&C.

abcd
sadasda

Find us on

Latest articles

Related articles

See more articles

The US agency warns that a prolonged government shutdown...

by David Shepardson WASHINGTON (Reuters) - The head of the Transportation Security Administration warned on Thursday...

Lilly’s Zepbound weight loss therapy becomes the first FDA-approved...

Author: Bhanvi Satiya (Reuters) - The U.S. Food and Drug Administration on Friday approved Eli Lilly's...

Here are the 10 highest growth stocks on the...

Image source: Getty Images The FTSEespecially...

Australian Wesfarmers sell Coregas to Nippon Sanso for $480...

Investing.com- Australian Wesfarmers Ltd (ASX:) will sell its industrial gas business Coregas to the unit of Japanese...